Management of the Central Nervous System Chronic Pelvic Pain

  • Marilena Gubbiotti
  • Antonella Giannantoni
Part of the Urodynamics, Neurourology and Pelvic Floor Dysfunctions book series (UNPFD)


The central sensitization is a central phenomenon of the nervous system with the enhanced responsiveness of the central neurons and there is no ongoing nociceptive stimulation from the periphery. The mechanisms contributing to pain amplification are heterogeneous and likely occur at various levels of the nervous system (NS); in the last years, neuroimaging techniques using magnetic resonance imaging have allowed the detailed description of the brain in patients with chronic pelvic pain (CPP). A number of treatments and management algorithms have been developed and applied in the treatment of CPP; indeed, the management of CPP required a multifaceted approach of the pharmacological therapy due to the multiple levels in the NS which act in the mechanism of action of pain.


Chronic pelvic pain Central nervous system Central sensitization Pharmacological therapy 


  1. 1.
    Nickel JC, Shoskes DA, Wagenlehner FH. Management of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS): the studies, the evidence, and the impact. World J Urol. 2013;31:747–53.PubMedCrossRefGoogle Scholar
  2. 2.
    As-Sanie S, Harris RE, Napadow V, Kim J, Neshewat G, Kairys A, Williams D, Clauw DJ, Schmidt-Wilcke T. Changes in regional gray matter volume in women with chronic pelvic pain: a voxel based morphometry study. Pain. 2012;153:1006–14.PubMedPubMedCentralCrossRefGoogle Scholar
  3. 3.
    Doggweiler R, Whitmore KE, Meijlink JM, Drake MJ, Frawley H, Nordling J, Hanno P, Fraser MO, Homma Y, Garrido G, Gomes MJ, Elneil S, van de Merwe JP, Lin ATL, Tomoe H. A standard for terminology in chronic pelvic pain syndromes: a report from the chronic pelvic pain working group of the international continence society. Neurourol Urodyn. 2017;36(4):984–1008.PubMedCrossRefGoogle Scholar
  4. 4.
    Apte G, Nelson P, Brismee JM, Dedrick G, Justiz R 3rd, Sizer PS Jr. Chronic female pelvic pain-Part 1: clinical pathoanatomy and examination of the pelvic region. Pain Pract. 2012;12:88–110.PubMedCrossRefGoogle Scholar
  5. 5.
    Linley JE, Rose K, Ooi L, Gamper N. Understanding inflammatory pain: ion channels contributing to acute and chronic nociception. Pflugers Arch. 2010;459:657–69.PubMedCrossRefGoogle Scholar
  6. 6.
    Zieglgansberger W, Berthele A, Tolle TR. Understanding neuropathic pain. CNS Spectr. 2005;10(4):298–308.PubMedCrossRefGoogle Scholar
  7. 7.
    McMahon SB, Dmitrieva N, Koltzenburg M. Visceral pain. Br J Anaesth. 1995;75(2):132–44.PubMedCrossRefGoogle Scholar
  8. 8.
    Wesselmann U, Baranowski AP, Borjesson M, Curran NC, Czakanski PP, Giamberardino MA, Ness TJ, Robbins MT, Traub RJ. Emerging therapies and novel approaches to visceral pain. Drug Discov Today Ther Strateg. 2009;6:89–95.PubMedPubMedCentralCrossRefGoogle Scholar
  9. 9.
    Giamberardino MA, Costantini R, Affaitati G, Fabrizio A, Lapenna D, Tafuri E, Mezzetti A. Viscero-visceral hyperalgesia: characterization in different clinical models. Pain. 2010;151:307–22.PubMedCrossRefGoogle Scholar
  10. 10.
    Nijs J, Goubert D, Ickmans K. Recognition and treatment of central sensitization in chronic pain patients: not limited to specialized care. J Orthop Sports Phys Ther. 2016;46(12):1024–8.PubMedCrossRefGoogle Scholar
  11. 11.
    Janicki TI. Chronic pelvic pain as a form of complex regional pain syndrome. Clin Obstet Gynecol. 2003;46:797–803.PubMedCrossRefGoogle Scholar
  12. 12.
    As-Sanie S, Harris RE, Napadow V, Kim J, Neshewat G, Kairys A, Williams D, Clauw DJ, Schmidt-Wilcke T. Changes in regional gray matter volume in women with chronic pelvic pain: a voxel-based morphometry study. Pain. 2012;153:1006–14.PubMedPubMedCentralCrossRefGoogle Scholar
  13. 13.
    Giesecke T, Gracely RH, Grant MA, Nachemson A, Petzke F, Williams DA, Clauw DJ. Evidence of augmented central pain processing in idiopathic chronic low back pain. Arthritis Rheum. 2004;50(2):613–23.PubMedCrossRefGoogle Scholar
  14. 14.
    Du MY, Wu QZ, Yue Q, Li J, Liao Y, Kuang WH, Huang XQ, Chan RC, Mechelli A, Gong QY. Voxelwise meta-analysis of gray matter reduction in major depressive disorder. Prog Neuro-Psychopharmacol Biol Psychiatry. 2012;36(1):11–6.CrossRefGoogle Scholar
  15. 15.
    Kutch JJ, Ichesco E, Hampson JP, et al. Brain signature and functional impact of centralized pain: a multidisciplinary approach to the study of chronic pelvic pain (MAPP) network study. Pain. 2017;158(10):1979–91.PubMedPubMedCentralCrossRefGoogle Scholar
  16. 16.
    Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the international continence society. Urology. 2003;61:37–49.PubMedCrossRefGoogle Scholar
  17. 17.
    van de Merwe JP, Nordling J, Bouchelouche P, Bouchelouche K, Cervigni M, Daha LK, Elneil S, Fall M, Hohlbrugger G, Irwin P, Mortensen S, van Ophoven A, Osborne JL, Peeker R, Richter B, Riedl C, Sairanen J, Tinzl M, Wyndaele JJ, et al. Diagnostic criteria, classification, and nomenclature for painful bladder syndrome/interstitial cystitis: an ESSIC proposal. Eur Urol. 2008;53(1):60–7.PubMedCrossRefGoogle Scholar
  18. 18.
    Homma Y, Ueda T, Tomoe H, Lin AT, Kuo HC, Lee MH, Lee JG, Kim DY, Lee KS, Interstitial cystitis guideline committee. Clinical guidelines for interstitial cystitis and hypersensitive bladder syndrome. Int J Urol. 2009;16:597–615.PubMedCrossRefGoogle Scholar
  19. 19.
    Sutcliffe S, Gallop R, Henry Lai HH, Andriole GL, Bradley CS, Chelimsky G, Chelimsky T, Quentin Clemens J, Colditz GA, Erickson B, Griffith JW, Kim J, Krieger JN, Labus J, Naliboff BD, Rodriguez LV, Sutherland SE, Taple BJ, Landis JR. “Multidisciplinary approach to the study of chronic pelvic pain” (MAPP) research network. BJU Int. 2019;Google Scholar
  20. 20.
    Shoskes DA, Curtis Nickel J, Kattan MW. Phenotypically directed multimodal therapy for chronic prostatitis/chronic pelvic pain syndrome: a prospective study using UPOINT. Urology. 2010;10:1249–53.CrossRefGoogle Scholar
  21. 21.
    Giannantoni A, Gubbiotti M, Yoshimura N, Andersson KE. Pharmacologic goals in interstitial cystitis/bladder pain syndrome. In: Hanno P, Nordling J, Wyndaele JJ, Staskin D, Wein A, editors. Bladder pain syndrome - an evolution. Berlin: Springer-Verlag; 2017. p. 87–94.Google Scholar
  22. 22.
    Engeler DS, Baranowski AP, Dinis-Oliveira P, Elneil S, Hughes J, Messelink EJ, van Ophoven A, Williams AC, European Association of Urology. The 2013 EAU guidelines on chronic pelvic pain: is management of chronic pelvic pain a habit, a philosophy, or a science? 10 years of development. Eur Urol. 2013;64:431–9.PubMedCrossRefGoogle Scholar
  23. 23.
    Hanno PM, Burks DA, Clemens JQ, Dmochowski RR, Erickson D, Fitzgerald MP, Forrest JB, Gordon B, Gray M, Mayer RD, Newman D, Nyberg L Jr, Payne CK, Wesselmann U, Faraday MM, Interstitial Cystitis Guidelines Panel of the American Urological Association Education and Research, Inc. AUA guideline for the diagnosis and treatment of interstitial cystitis/bladder pain syndrome. J Urol. 2011;185:2162–70.PubMedCrossRefGoogle Scholar
  24. 24.
    Siden HB, Carleton BC, Oberlander TF. Physician variability in treating pain and irritability of unknown origin in children with severe neurological impairment. Pain Res Manag. 2013;18(5):243–8.PubMedPubMedCentralCrossRefGoogle Scholar
  25. 25.
    Fall M, Logadottir Y, Peeker R. Interstitial cystitis is bladder pain syndrome with Hunner’s lesion. Int J Urol. 2014;21(Suppl 1):79–82.PubMedCrossRefGoogle Scholar
  26. 26.
    Tamano R, Ishida M, Asaki T. Effect of spinal monoaminergic neuronal system dysfunction on pain threshold in rats, and the analgesic effect of serotonin and norepinephrine reuptake inhibitors. Neurosci Lett. 2016;615:78–82.PubMedCrossRefGoogle Scholar
  27. 27.
    van Ophoven A, Pokupic S, Heinecke A, Hertle L. A prospective, randomized, placebo controlled, double-blind study of amitriptyline for the treatment of interstitial cystitis. J Urol. 2004;172:533–6.PubMedCrossRefGoogle Scholar
  28. 28.
    Foster HE, Hanno PM, Nickel JC, et al. Effect of amitriptyline on symptoms in treatment naive patients with interstitial cystitis/painful bladder syndrome. J Urol. 2010;183:1853–8.PubMedPubMedCentralCrossRefGoogle Scholar
  29. 29.
    An update on the drug treatment of neuropathic pain. Part 1: antidepressants. Drug Ther Bull. 2012;50:114–7.Google Scholar
  30. 30.
    Godfrey RG. A guide to the understanding and use of tricyclic antidepressant in the overall management of fibromyalgia and other chronic pain syndromes. Arch Intern Med. 1996;156:1047–52.PubMedCrossRefGoogle Scholar
  31. 31.
    Hauer J, Houtrow AJ. Pain assessment and treatment in children with significant impairment of the central nervous system. Pediatrics. 2017;139(6):e20171002.PubMedCrossRefGoogle Scholar
  32. 32.
    Sator-Katzenschlager SM, Scharbert G, Kress HG, Frickey N, Ellend A, Gleiss A, Kozek-Langenecker SA. Chronic pelvic pain treated with gabapentin and amitriptyline: a randomized controlled pilot study. Wien Klin Wochenschr. 2005;117:761–8.PubMedCrossRefGoogle Scholar
  33. 33.
    Baranowski AP, Lee J, Price C, et al. Pelvic pain: a pathway for care developed for both men and women by the British pain society. Br J Anaesth. 2014;112(3):452–9.PubMedCrossRefGoogle Scholar
  34. 34.
    Lee M, Silverman SM, Hansen H, Patel VB, Manchikanti L. A comprehensive review of opioid-induced hyperalgesia. Pain Physician. 2011;14:145–61.PubMedGoogle Scholar
  35. 35.
    Baber Z, Erdek MA. Failed back surgery syndrome: current perspectives. J Pain Res. 2016;9:979–87.PubMedPubMedCentralCrossRefGoogle Scholar
  36. 36.
    Carey ET, Till SR, As-Sanie S. Pharmacological management of chronic pelvic pain in women. Drugs. 2017;77(3):285–301.PubMedCrossRefGoogle Scholar
  37. 37.
    Gardner JS, Blough D, Drinkard CR, Shatin D, Anderson G, Graham D, Alderfer R. Tramadol and seizures: a surveillance study in a managed care population. Pharmacotherapy. 2000;20(12):1423–31.PubMedCrossRefGoogle Scholar
  38. 38.
    Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, Felder CC, Herkenham M, Mackie K, Martin BR, Mechoulam R, Pertwee RG. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev. 2002;54:161–202.PubMedCrossRefGoogle Scholar
  39. 39.
    Racz I, Nadal X, Alferink J, Baños JE, Rehnelt J, Martín M, Pintado B, Gutierrez-Adan A, Sanguino E, Manzanares J, Zimmer A, Maldonado R. Crucial role of CB(2) cannabinoid receptor in the regulation of central immune responses during neuropathic pain. J Neurosci. 2008;28:12125–35.PubMedPubMedCentralCrossRefGoogle Scholar
  40. 40.
    Muehlbacher M, Nickel MK, Kettler C, Tritt K, Lahmann C, Leiberich PK, Nickel C, Krawczyk J, Mitterlehner FO, Rother WK, Loew TH, Kaplan P. Topiramate in treatment of patients with chronic low back pain: a randomized, double-blind, placebo-controlled study. Clin J Pain. 2006;22:526–31.PubMedCrossRefGoogle Scholar
  41. 41.
    Rivera Día RC, Lotero MAA, Suarez MVA, et al. Botulinum toxin for the treatment of chronic pain. Review of the evidence. Colomb J Anesthesiol. 2014;42:205–13.CrossRefGoogle Scholar
  42. 42.
    Antonucci F, Rossi C, Gianfranceschi L, Rossetto O, Caleo M. Long-distance retrograde effects of botulinum neurotoxin A. J Neurosci. 2008;28(14):3689–96.PubMedPubMedCentralCrossRefGoogle Scholar
  43. 43.
    Vacca V, Marinelli S, Luvisetto S, Pavone F. Botulinum toxin A increases analgesic effects of morphine, counters development of morphine tolerance and modulates glia activation and μ opioid receptor expression in neuropathic mice. Brain Behav Immun. 2013;32:40–50.PubMedCrossRefGoogle Scholar
  44. 44.
    Bettoni I, Comelli F, Colombo A, Bonfanti P, Costa B. Non-neuronal cell modulation relieves neuropathic pain: efficacy of the endogenous lipid palmitoylethanolamide. CNS Neurol Disord Drug Targets. 2013;12(1):34–44.PubMedCrossRefGoogle Scholar
  45. 45.
    Alhouayek M, Muccioli GG. Harnessing the anti-inflammatory potential of palmitoylethanolamide. Drug Discov Today. 2014;19(10):1632–9.PubMedCrossRefGoogle Scholar
  46. 46.
    Rao S, Song Y, Peddie F, Evans AM. Particle size reduction to the nanometer range: a promising approach to improve buccal absorption of poorly water-soluble drugs. Int J Nanomedicine. 2011;6:1245–51.PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  • Marilena Gubbiotti
    • 1
  • Antonella Giannantoni
    • 2
  1. 1.Department of UrologySan Donato HospitalArezzoItaly
  2. 2.Department of Medical and Surgical Sciences and Neurosciences, Functional and Surgical Urology UnitUniversity of SienaSienaItaly

Personalised recommendations